After successfully presenting Hepatoscope at the DDW conference in San Diego and EASL in Amsterdam, French medical ultrasound company E-Scopics is continuing to present its unique liver assessment software system at the June 2025 American Diabetes Association conference in Chicago. Hepatoscope is seeing increasing adoption, with the company reporting deployments at several major institutions in the United States and Europe, validating its clinical and commercial viability.
In just a few years, the company has successfully adapted its high-end ultrafast imaging systems to the needs of hepato-gastroenterology and diabetology departments, making the system available to a growing number of users who recognize its clinical value and its importance in improving medical care. E-Scopics has completely changed the game in the field of portable ultrasound scanners by leveraging proprietary technology using software-based image reconstruction algorithms. In 2023, E-Scopics began marketing this first product, Hepatoscope, in the United States and EMEA countries. The company’s medium-term goal is to increase its global footprint, where patients at risk for chronic liver disease are located, beginning its expansion in most European countries. In the United States, Hepatoscope has gained recognition from large institutions and healthcare facilities of all sizes as an alternative to existing technology.
Claude Cohen-Bacrie, founder and CEO of E-Scopics, who brings his extensive experience in developing and bringing cutting-edge ultrasound technologies to market, says: “Our ambition is to bring high-end quantitative ultrasound modalities and tools as close as possible to the patient, to make them available to users who are not necessarily ultrasound experts, for the benefit of healthcare systems, for the benefit of patients. Making the care pathway simpler and more efficient is our priority. We are very pleased to be able to count on our supporters, committed to our long-term commitment with such enthusiasm, whether they are Hepatoscope users who have understood its full clinical potential or commercial partners attracted by the scope of the commercial opportunities.”
The company recognized early on the public health problem of metabolic-associated fatty liver disease (MASLD), which is on the rise worldwide, and the need to provide the medical community with a more accessible, easier-to-use, and highly portable tool to accurately screen for the disease. The initial goal was clear: to develop a simple-to-use tool and reduce costs. The Hepatoscope application is easily downloaded onto a consumer laptop or tablet and quickly deployable in the field. Beyond its ease of use, the company offers a subscription-based marketing model, making it easier for any clinic to access, through an equally innovative marketing approach.
Cohen-Bacrie added: “We are convinced that healthy and fair competition between industrial players helps stimulate innovation, for the benefit of patients and a healthier population. It would be impossible today to talk about elastography in an environment that had not experienced this significant competition. Regarding liver assessment specifically, patients really need our technology, clinicians are asking for more powerful and affordable diagnostic tools, and regulatory authorities as well as health insurers have accepted it.”
The numbers bear this out. Approximately 1.5 million patients have been diagnosed with metabolic-associated steatohepatitis (MASH) in the United States, and the precursor to MASH, MASLD, is estimated to affect more than half of all American adults by 2040. The natural history of MASLD ranges from simple, usually nonprogressive, fat accumulation in the liver to MASH, which can lead to cirrhosis, hepatocellular carcinoma, and death. The cost attributed to complications of MASLD in the United States exceeds $100 billion annually. Therefore, it is important to identify these patients and manage them as early as possible.
“As consumers, we’ve been conditioned to expect the latest computing and communications tools to be increasingly powerful; and they’re simply making us more and more efficient in our daily tasks,” says Dr. Julio Gutierrez, associate professor of medicine at the Scripps Center for Organ Transplant in La Jolla, California, and an early adopter of Hepatoscope. “For me, E-Scopics feels like Apple. I expect the ability to continuously innovate, and so far the clinical impact has been significant.”
Dr. Cyrielle Caussy, MD, PhD, Professor of Nutrition and Endocrinologist-Diabetes at Lyon 1 University and Lyon Sud Hospital in France, says, “In endocrinology and diabetology departments, approximately 80% of patients screened have low liver stiffness, meaning they can be reassured without further specialist consultation or testing. By reducing the time between initial screening and specialist care, Hepatoscope improves both the efficiency and quality of patient care. For high-risk patients, we can initiate care pathways much earlier, which can slow or stop the progression of liver disease. For low-risk individuals, we avoid unnecessary specialist consultations, freeing up resources and improving the overall efficiency of the healthcare system. Importantly, patients appreciate the immediate feedback they receive, which encourages adherence to treatment and lifestyle modification programs.”
E-Scopics will be demonstrating the Hepatoscope extensively at the American Diabetes Association’s annual conference in Chicago, at its booth #3725. Visitors can schedule a demonstration by emailing joel.gay@e-scopics.com.
About E-Scopics:
E-Scopics SAS is a Medtech company based in France. The company is dedicated to developing the accessibility and ease of use of high-end ultrasound tools closer to the patient. Its agile software platform dematerializes and automates ultrasound imaging technologies. The products derived from this platform are ultrasound services, specific applications, marketed on a fee-for-service or subscription basis. The company’s first product, Hepatoscope, leverages quantitative imaging capabilities to help healthcare practitioners assess the risks of hepatic fibrosis and steatosis, important markers of MASLD-MASH, non-invasively at the patient’s bedside. To learn more, visit www.escopics.com .
The translated text of the press release should in no way be considered official. The only authoritative version of the press release is the one in its original language. The translation should always be compared with the source text, which will be the legal precedent.
